Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Director departure
Appointed director
CC transcript
FOXO TECHNOLOGIES INC. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Demand Promissory Note 2"
08/23/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
08/18/2023 8-K Quarterly results
08/10/2023 8-K Quarterly results
Docs: "FOXO TECHNOLOGIES INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS"
08/08/2023 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
07/21/2023 8-K Quarterly results
07/20/2023 8-K Quarterly results
06/16/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements MINNEAPOLIS, MN, JUNE 16, 2023 — On June 12, 2023, FOXO Technologies Inc. received an official notice of noncompliance from NYSE Regulation stating that the Company is below compliance with Section 1003 in the NYSE American Company Guide since it reported stockholders’ deficit of $ at March 31, 2023, and losses from continuing operations and/or net losses in its two most recent fiscal years ended December 31, 2022. Section 1003 of the Company Guide requires a listed company to have stockholders’ equity of $2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. The Company is now subject..."
05/30/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "FOXO Technologies Announces Results of Annual Stockholders Meeting"
05/17/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "NYSE American Has Commenced Delisting Proceedings in the FOXO WS warrants of FOXO Technologies Inc. MINNEAPOLIS, MN, MAY 17, 2023 — On May 15, 2023 NYSE American LLC provided written notice to FOXO Technologies Inc. that NYSE American had halted trading in the Company’ s warrants, each exercisable for one share of the Company’ s Class A common stock at an exercise price per share of $11.50, ticker symbol FOXO WS , on NYSE American due to the low trading price of the Warrants. On May 16, 2023, NYSE American provided written notice to the Company and publicly announced that NYSE Regulation has determined to commence proceedings to delist the Warrants and that the Warrants are no longer suitable for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading pr..."
05/11/2023 8-K Quarterly results
Docs: "FOXO Technologies™ Announces First Quarter 2023 Financial Results MINNEAPOLIS, MN, MAY 11, 2023 — FOXO Technologies Inc. , a leader in commercializing epigenetic biomarkers of health and aging, today reported financial results for the first quarter ended March 31, 2023. “The first quarter was a strong start to the year, and I am very pleased by our continued execution in support of our strategic goals,” said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. “We recently announced the launch of our direct-to-consumer FOXO Longevity Report™ beta, which represents the next stage in FOXO’ s evolution and expands on our successes in the insurance market. We believe this significant milestone will serve to improve the scale of our customer engagement platform while e..."
04/18/2023 8-K Quarterly results
03/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Dated: March 30, 2023 Attorneys for Petitioner FOXO Technologies Inc."
03/31/2023 8-K Conference call transcript
Docs: "FOXO Technologies™ Announces Full Year 2022 Financial Results and Recent Business Highlights MINNEAPOLIS, MN, MARCH 30, 2023 — FOXO Technologies Inc. , a leader in commercializing epigenetic biomarkers of health and aging in life insurance, today reported financial results for the full year ended December 31, 2022 and accompanying business highlights. “I am truly excited with the future we are building,” said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. “The challenges faced in 2022 presented us with an opportunity to take a comprehensive assessment of our business and the way we approach the market. We sought to reset our vision and mission, and identify the clear objectives that we believe are necessary to achieve them and hold ourselves accountable. Our aim i...",
"Transcript of Conference Call held on March 30, 2023"
03/20/2023 8-K Quarterly results
03/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MEMORANDUM, DATED MARCH 9, 2023"
02/08/2023 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits  Interactive Data
02/06/2023 8-K/A Quarterly results
02/03/2023 8-K Quarterly results
02/02/2023 8-K Resignation/termination of a director
Docs: "JON SABES RESIGNATION LETTER, DATED JANUARY 29, 2023",
"Letter from Jon Sabes"
01/12/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "RECITALS"
01/06/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/15/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Departure of Directors or Certain...
Docs: "AMENDMENT TO FORWARD SHARE PURCHASE AGREEMENT"
09/26/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION",
"LETTER TO STOCKHOLDERS, DATED SEPTEMBER 26, 2022"
09/21/2022 8-K Director compensation was amended/approved, Appointed a new director
Docs: "CERTIFICATE OF INCORPORATION OF FOXO TECHNOLOGIES INC",
"BYLAWS OF FOXO TECHNOLOGIES INC",
"FORM OF ASSUMED WARRANT",
"FORM OF 15% SENIOR PROMISSORY NOTE",
"FOXO TECHNOLOGIES INC. 2022 EQUITY INCENTIVE PLAN",
"FOXO TECHNOLOGIES INC. 2020 EQUITY INCENTIVE PLAN",
"FORM OF FOXO TECHNOLOGIES INC. 2020 EQUITY INCENTIVE PLAN AWARD AGREEMENTS",
"Recitals",
"FORM OF REVISED BACKSTOP SUBSCRIPTION AGREEMENT, DATED SEPTEMBER 13, 2022",
"INSIDER LETTER AMENDMENT"
09/16/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PRESS RELEASE, DATED AS OF SEPTEMBER 16, 2022."
09/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Delwinds Insurance Acquisition Corp. Announces Requests to Redeem Public Shares"
09/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "1021 Main Street, Suite 1960"
07/06/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
02/25/2022 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Regulation...
Docs: "PROMISSORY NOTE Principal Amount: Up to $2,000,000.00 Dated as of February 23, 2022 New York, New York Delwinds Insurance Acquisition Corp., a Delaware corporation , promises to pay to the order of DIAC Sponsor LLC, a Delaware limited liability company, or its registered assigns or successors in interest , or order, the principal sum of up to Two Million Dollars in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as Payee may from time to time designate by written notice in accordance with the provisions of this Note. 1. Repayment. The principal balance of this Note shall be payable on the earliest...",
"INVESTOR DECK",
"SCRIPT TO INVESTOR PRESENTATION",
"MODERNIZING UNDERWRITING WITH EPIGENTICS AND MACHINE LEARNING According to LIMRA International, Inc., an international research association for life insurance and financial services companies, among the most significant current issues in the life insurance industry are the lengthy timelines and invasive blood and urine specimen requirements associated with underwriting. FOXO is at the forefront of commercializing proprietary saliva-based epigenetic biomarkers with a plan to create a simpler, smoother, non-invasive underwriting process. FOXO expects its seamless saliva based underwriting process to provide enhanced protective value and represent a step-change improvement to the global life insurance industry. FOXO’ s proprietary epigenetic biomarker technology is designed to address the sam..."
05/07/2021 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
01/26/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy